Bright RA (2000) Special methodological issues in the pharmacoepidemiology studies of devices. In: Strom, BL, ed., Pharmacoepidemiology, 3rd edn. New York: Wiley, pp. 733-47.
Brown SL, Middleton MS, Berg WA, Soo MS, Pennello G (2000) Prevalence of rupture of silicone gel breast implants revealed on magnetic resonance imaging in a population of women in Birmingham, Alabama. Am J Radiol 175: 1057-64.
Cardiology (1997) FDA alerts device manufacturers. Cardiology 26(10): 7.
Dickinson's FDA Review (1997) FDA detective work on implants gets grip on vacuum hazard. Dickinson's FDA Review September: 22.
DoLuu HM, Hutter JC, Bushar HF (1998) A physiologically based pharmacokinetic model 2,4-toluene-diamine leached from polyurethane foam-covered breast implants. Environ Health Perspect 106(7): 393-400.
ECRI (1998) Medical device problem reporting for the betterment of healthcare. Health Devices 27(8): 27792.
Food and Drug Administration (1995) TDA and polyurethane breast implants. Food and Drug Administration Talk Paper. Rockville, MD: US Food and Drug Administration.
Food and Drug Administration (1997). Vacuum loss in resonating components. FDA Dear Manufacturer Letter. Rockville, MD: US Food and Drug Administration.
Food and Drug Administration (1999a) Designing a medical device surveillance network. FDA Report to Congress. Rockville, MD: US Food and Drug Administration.
Food and Drug Administration (1999b) Managing the risks from medical product use: creating a risk management framework. Report to the FDA Commissioner from the Task Force on Risk Management. Rockville, MD: US Food and Drug Administration.
Gallivan M (1997) The 1997 Global Medical Technology Update: The Challenges Facing U.S. Industry and Policy Makers. Washington, DC: Health Industry Manufacturers Association, pp. 37 -51.
Hester TR Jr, Ford NF, Gale PJ, Hammett JL, Raymond R, Turnbull D, Frankos VH, Cohen MB (1997) Measurement of 2,4-toluenediamine in urine and serum samples from women with Meme or Replicon breast implants. Plast Reconstr Surg 100(5): 1291-8.
Kessler DA (1993) Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. J Am Med Assoc 269: 2765-8.
Lewin Group, Inc. (2000) State of the Industry, Year 2000. Report 1 for AdvaMed, pp. 3-6.
Marinac-Dabic D, Kennard ED, Torrence ME (1998) Palmaz-Schatz stenting in women: acute and long-term outcomes. APHA 126th Annual Meeting, Washington, DC [Abstract].
Silverman BG, Brown SL, Bright RA, Kaczmarek RG, Arrowsmith-Lowe JB, Kessler DA (1996) Reported complications of silicone gel breast implants: an epidemiologic review. Ann Intern Med 124: 744-56.
Wilkerson Group (1995) Forces Reshaping the Performance and Contribution of the U.S. Medical Device Industry. New York, pp. 3-31.
Pharmacovigilance. Edited by R.D. Mann and E.B. Andrews © 2002 John Wiley & Sons, Ltd ISBN: 0-471-49441-0
Was this article helpful?